Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Patent
1994-06-10
1996-11-26
Russel, Jeffrey E.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
514 21, A61K 3817
Patent
active
055785700
ABSTRACT:
A method of treating septic shock in a mammal including the administration of a septic shock-treating effective amount of thymosin .beta..sub.4 (T.beta..sub.4) to the mammal. Included is a process directed to obstructing the progression of sepsis cascade by administration of a sepsis cascade progression-obstructing amount of T.beta..sub.4. Further included is a process directed to preventing septic shock by administration of a septic shock-preventing effective amount of T.beta..sub.4.
REFERENCES:
patent: 4297276 (1981-10-01), Goldstein et al.
patent: 4395404 (1983-07-01), Low et al.
patent: 5055447 (1991-10-01), Palladino et al.
patent: 5260224 (1993-11-01), Stossel et al.
patent: 5464817 (1995-11-01), Stossel et al.
Ishitsuka et al., "Protective Activity of Thymosin Against Opportunistic Infections in Animal Models", Cancer Immunology Immunotheraphy. 14:3, pp. 145-150, Mar. 1983.
Ashkenazi et al., "Protection against endotoxic shock by a tumor necrosis factor receptor immunoadhesin", Proc. Natl. Acad. Sci. USA, 88:23, pp. 10535-10539, Dec. 1, 1991.
Watt et al., "Alterations in plasma levels and complexing of Gc (vitamin D-binding protein) in rats with endotoxic shock", Biological Abstracts 88:7, Abstract No. 75029, 1989 (Circ Shock, 28:3, pp. 279-292, 1989).
Sawada, Shuzo, et al., "Protection against Infection with Pseudomonas aeruginosa by Passive Transfer of Monoclonal Antibodies to Lipopolysaccharides and Outer Membrane Proteins," J. of Inf. Diseases, 150:4 (Oct. 1984).
Low, Teresa L. K., et al., "Thymosins: structure, function and therapeutic applications," Thymus 6, pp. 27 et seq. (1984).
Teng, Nelson N. H., et al., "Protection against Gram-negative bacteremia and endotoxemia with human monoclonal IgM antibodies," Proc. Natl. Acad. Sci., vol. 82, pp. 1790-1794 (Mar. 1985).
Webster's Third New International Dictionary, p. 1798 (1986).
Dorland's Illustrated Medical Dictionary, 26th ed., p. 1026 (not dated).
Baumgartner, J. D., et al., "Asociation between Protective Efficacy of Anti-Lipopolysaccharide (LPS) Antibodies and Suppression of LPS-Induced Tumor Necrosis Facto .alpha. and Interleukin 6," J. Exp. Med., 171:889-896 (Mar. 1990).
Safer, Daniel, et al., "Thymosin .beta..sub.4 and Fx, an Actin-sequestering Peptide, Are Indistinguishable," J. of Biol. Chem., vol. 266, No. 7, pp. 4029-4032 (Mar. 1991).
Lee, William M., et al., "The Extracellular Actin-Scavenger System and Actin Toxicity," New England J. of Med., vol. 326, No. 20, pp. 1335-1341 (May 14, 1992).
Sanders, Mitchell C., et al., "Thymosin .beta..sub.4 (Fx peptide) is a potent regulator of actin polymerization in living cells," Proc. Natl. Acad. Sci., vol. 89, pp. 4678-4682 (May 1992).
Cross et al, Infection and Immunity vol. 61 p. 2741 (1993).
Fitzer-Schiller, Washington Post, Jan. 19, 1993 p. D3.
Biotechnology Newswatch, Aug. 1, 1994 pp. 1 and 4.
Fagarasan Mirela O.
Goldstein Allan L.
Russel Jeffrey E.
The George Washington University Medical Center
LandOfFree
Method of treating septic shock using thymosin .beta..sub.4 does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of treating septic shock using thymosin .beta..sub.4, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of treating septic shock using thymosin .beta..sub.4 will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1973161